Get the Stockscreener App
225.09
3.12%
-7.25
After Hours:
225.09
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $225.09, with a volume of 306.52K.
It is down -3.12% in the last 24 hours and up +10.93% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$232.34
Open:
$230.43
24h Volume:
306.52K
Relative Volume:
1.29
Market Cap:
$4.49B
Revenue:
$268.09M
Net Income/Loss:
$124.45M
P/E Ratio:
38.58
EPS:
5.8347
Net Cash Flow:
$38.05M
1W Performance:
+8.17%
1M Performance:
+10.93%
6M Performance:
+22.80%
1Y Performance:
+110.76%
1-Day Range:
$221.77
$230.43
1-Week Range:
$198.55
$234.76
52-Week Range:
$98.89
$234.76
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
225.09 | 4.63B | 268.09M | 124.45M | 38.05M | 5.8347 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | BofA Securities | Buy |
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $243 - GuruFocus
Travere, Ligand Pharma announce FDA label expansion for Filspari - MSN
Ligand (LGND) Partners with Travere on FDA Approval for Filspari - GuruFocus
H.C. Wainwright raises Ligand Pharma price target on royalty growth By Investing.com - Investing.com Canada
Ligand Pharmaceuticals stock hits 52-week high at 228.09 USD By Investing.com - Investing.com Canada
Travere, Ligand win FDA label expansion for Filspari (TVTX) - Seeking Alpha
First approved FSGS drug gives Ligand a 9% sales royalty - Stock Titan
Free cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView — Track All Markets
Cash per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView — Track All Markets
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
S P Trends: Will Ligand Pharmaceuticals Incorporated benefit from rising consumer demandEntry Point & Comprehensive Market Scan Reports - baoquankhu1.vn
Ligand Pharmaceuticals Incorpor (LGND) Stock forecasts - Yahoo Finance UK
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
LGND Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Chart Watch: Will Ligand Pharmaceuticals Incorporated benefit from rising consumer demandTrade Volume Report & Weekly High Return Stock Forecasts - baoquankhu1.vn
Tech Rally: Is Ligand Pharmaceuticals Incorporated being accumulated by smart money2026 Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Allspring Global Investments Holdings LLC Has $13.65 Million Position in Ligand Pharmaceuticals Incorporated $LGND - marketbeat.com
LGND Technical Analysis & Stock Price Forecast - Intellectia AI
LGND Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year - Yahoo Finance
EBIT per share of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Ligand Pharmaceuticals director Kozarich sells $94k in stock By Investing.com - Investing.com Australia
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 Shares - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares - MarketBeat
Ligand Pharmaceuticals director Kozarich sells $94k in stock - Investing.com
Planned sales: Ligand Pharmaceuticals (LGND) director trims 467 shares - Stock Titan
Ligand Pharmaceuticals CLO sells $1m in shares By Investing.com - Investing.com India
Ligand Pharmaceuticals CLO sells $1m in shares - Investing.com
Ligand (NASDAQ: LGND) CLO sells 5,000 shares after exercising stock options - Stock Titan
Board member Todd Davis (PTHS) updates Pelthos stock grants and holdings - Stock Titan
LGND (NASDAQ: LGND) Rule 144 sales — 467 shares on three dates - Stock Titan
Insider Move: John L LaMattina Exercises Options, Realizing $185K At Ligand Pharmaceuticals - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Passes Minervini Trend Template and Growth Screen - ChartMill
Ligand Pharma CLO Sells $1.03M in Stock | Transaction Details & Company BackgroundNews and Statistics - IndexBox
Ligand Pharmaceuticals director LaMattina sells $433k in shares By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals director LaMattina sells $433k in shares - Investing.com
Ligand (NASDAQ: LGND) director exercises options, sells 2,161 common shares - Stock Titan
LIGAND PHARMACEUTICALS INCORPORATED (LGND) - MSN
CLO Sells LGND 5,000 Shares for $1.0 Million - AOL.com
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):